Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Abstract: Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody.

Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.

Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.

Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.

Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.

Abstract: A releasing structure for a lancing device according to an exemplary embodiment of the present invention may include: a lancet body with a lancet at the front; a lancet holder mounted with the lancet body with the lancet at the front; a stem disposed behind the lancet holder and moving the lancet holder forward/backward; a rotary housing pushing/pulling the stem while turning forward at a predetermined angle about a rotational axis defined in the movement direction of the lancet; a torsion spring storing torque for turning the rotary housing forward at a predetermined angle; and a loading handle transmitting torque to the torsion spring while turning forward at a predetermined angle.

Abstract: Provided is a video encoding method for a parallel process. The video encoding method includes performing an inter prediction and an intra prediction for pictures included in a group of picture (GOP) and determining an encoding order and reference dependency between the pictures included in the GOP, and generating a predetermined data unit including reference relation information generated based on the encoding order and reference dependency between the pictures included in the GOP.

Abstract: An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided.

Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.

Abstract: A video encoding and decoding methods and apparatuses for performing the methods thereof are provided. The video encoding method includes: determining a region in a current image having a change in at least one of a scale and an angle with respect to a reference image; generating variation information representing a variation in at least one of the scale and the angle between the region in the current image and a reference region in the reference image corresponding to the region in the current image; and encoding residual information representing a difference between a predicted sample value from the reference image and a sample value of the current image based on the generated variation information.

Abstract: The disclosure is related to selecting and allocating one of resources in a cloud computing system to create a virtual machine. A control server may determine a resource selection reference by selecting one of fault-tolerance and network efficiency upon receipt of a request message for creating a target virtual machine. The control server may calculate at least one of a fault-tolerance point and a network efficiency point of each candidate resource according to the selected resource selection reference. The control server may select one of candidate resources to create a requested virtual machine based on at least one of the calculated fault-tolerance point and the calculated network efficiency point of the candidate resources.

Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: The disclosure is related to a method for distributing data traffic of a wireless local area network (WLAN) in a WLAN access network while providing service continuity and internet protocol (IP) mobility in a heterogeneous network environment. The method may include receiving data traffic generated by user equipment and from a wireless local area network, selecting one of a first data path and a second data path for the received data traffic based on path decision information associated with the received data traffic, and transmitting the data traffic to Internet through the selected data path. The first data path may transmit the data traffic to Internet through a packet data network (PDN) gateway and the second data path may transmit the data traffic to Internet without passing through the PDN gateway.

Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a c-Myc Inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of a c-Myc inhibitor as an active ingredient, packaged together.

Abstract: A method of preventing and/or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.

Abstract: A method of selecting a subject for administration of an anti-c-Met antibody, comprising (i) determining the presence or the amount of a ubiquitin peptidase, (ii) determining the presence or expression level of a ubiquitin peptidase coding gene, or (iii) measuring the activity of a ubiquitin peptidase, in a biological sample; as well as related methods.